OPTIC is part of the largest clinical program in TED and demonstrates that Tapezza provides significant improvements in proptosis (eye bulging) and diplopia (double vision) compared to placebo.
Tapezza is a fully human monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) that is administered to patients once every three weeks for a total of eight infusions.
Tapezza was approved by the US Food and Drug Administration on January 21, 2020 making it the first and only medicine approved for the treatment of TED. The medicine received Priority Review, Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.
OPTIC compared the efficacy and safety of Tapezza to placebo administered by infusion once every three weeks for a total of eight infusions. As previously reported, the trial met its primary endpoint and all secondary endpoints.
At Week 24, more patients receiving Tapezza versus placebo had a ≥ 2 mm reduction of proptosis in the study eye, without deterioration in the fellow eye (p
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial